Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emergence Of New Myeloma Drugs, And Combinations, Raises Red Flag On Costs

Executive Summary

Combinations of two or more branded drugs likely mean better potency and sales across the board, but mounting costs are likely to raise red flag with payers.

You may also be interested in...



Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.

J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A

Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.

Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test

Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.

Topics

Related Companies

UsernamePublicRestriction

Register

PS056960

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel